Henry Shin had a terrible headache. The 47-year-old Chinese American furniture mover was usually able to work through aches and pains, but this headache had continued for the past two weeks. He tried over-the-counter medicines—and acupuncture—but nothing seemed to help. When he noticed his vision becoming more blurry, he decided it was finally time to see a doctor.

Examination revealed mild vitreous inflammation, mild hyperemia of the disc, and serous macular detachment in both eyes (Fig. 2A). Fluorescein angiography (FA) revealed late pinpoint hyperfluorescence at the level of the retinal pigment epithelium (RPE) with late, progressive filling of the serous retinal detachment spaces and late leakage of the optic discs bilaterally (Fig. 2B). Spectral domain ocular coherence tomography (SD-OCT) confirmed the presence of bilateral serous macular detachments (Fig. 2C).

Workup and Treatment
A laboratory workup was obtained, including the following tests: serum rapid plasma reagin (RPR), fluorescent treponemal antibody absorption (FTA-ABS), angiotensin-converting enzyme (ACE), lysozyme, Quantiferon-TB (for tuberculosis), complete blood count (CBC), and liver function tests (LFT). All results were either negative or within normal limits. While waiting for the final results of his laboratory examinations, we started Mr. Shin on 100 mg of oral prednisone daily, as well as topical prednisolone acetate and homatropine eye drops. After his studies came back as negative or within normal limits, we added oral azathioprine at a dosage of 50 mg daily. Over the course of several months, as the inflammation and subretinal fluid resolved, we were able to taper Mr. Shin off the oral prednisone and topical medications. Meanwhile, the azathioprine was increased to a dose-
age of 200 mg daily, with close monitoring of his CBC and LFT. Visual acuity at his last visit, 17 months after his initial presentation, was 20/25 in the right eye and 20/400 in the left eye.

**Discussion**

Sympathetic ophthalmia is a rare bilateral granulomatous uveitis that occurs following eye trauma or surgery. The eye that experienced the trauma or surgery is referred to as the exciting or inciting eye, whereas the fellow eye is called the sympathizing eye. Inciting events can include any type of injury or surgery—from an ocular contusion to a ruptured globe, and from penetrating procedures such as cataract surgery or vitrectomy to nonpenetrating procedures such as cycloecryotherapy and proton beam irradiation.

**How long until onset?** The time from ocular injury to onset of SO can vary widely, from two weeks to over 50 years, but approximately 80 percent of cases occur within three months and 90 percent occur within one year. Past studies estimated the incidence of SO to be 0.1 percent following intraocular surgery and 0.2 to 0.5 percent after open globe injury. A more recent study looked at the incidence of SO in 59 million citizens of the United Kingdom and Ireland over a 15-month period. It found an incidence of 0.03 per 100,000 population, with the most common risk factor being ocular surgery, especially retinal surgery.

**How does it develop?** The cause of SO is unclear. Current theories point to an autoimmune response directed against one or more uveal antigens following trauma or surgery. Genetic factors may also play a role, since associations with major histocompatibility complex (MHC) haplotypes HLA-DR4/DQw3, HLA-DR4/DRw52, HLA-A11, HLA-B40, HLA-DRB1*04, and HLA-DQB1*04 have been shown.

**How is it diagnosed?** The diagnosis of SO is based primarily on a consistent clinical history and findings. Laboratory studies are used to rule out other diagnoses, including sarcoidosis, tuberculosis, and syphilis. B-scan ultrasonography is used to exclude posterior scleritis.

SO should be considered in all patients with bilateral uveitis and history of ocular trauma or surgery. Typical symptoms include blurry vision, pain, and photophobia. Anterior segment examination may show conjunctival injection, anterior chamber inflammation, large or small keratic precipitates, and posterior synechiae. Posterior segment examination may show moderate to severe vitritis, papillitis, exudative retinal detachments, and yellow-white choroidal lesions known as Dalen-Fuchs nodules. Extraocular findings are uncommon but can include headache, hearing disturbance, alopecia, poliosis, and vitiligo, as seen in VKH disease. Ocular complications can include secondary glaucoma, cataract, macular scarring or atrophy, optic atrophy, and, rarely, choroidal neovascularization. Phthisis of the sympathizing eye can occur, but it is uncommon with prompt and aggressive use of immunosuppressive agents.

**What do you look for in imaging?** FA often shows punctate hyperfluorescence at the level of the RPE followed by progressive filling of serous detachment spaces, as in our patient. Dalen-Fuchs nodules, which are present in 25 to 30 percent of cases, may be either hypo- or hyperfluorescent, depending on the state of the overlying RPE. Disc leakage and macular edema may occur. SD-OCT can show serous retinal detachments, disorganization and thinning of the retina, and choroidal thickening.

**What does histopathology show?** There is a diffuse, bilateral granulomatous nonnecrotizing inflammatory reaction. Thickening of the choroid results from infiltration of mononuclear and epithelioid cells. The choriocapillaris and retina are often, but not always, spared. Dalen-Fuchs nodules appear as collections of lymphocytes, histiocytes, and depigmented RPE cells beneath Bruch’s membrane.

**How is it treated?** Systemic corticosteroids constitute the first-line therapy for SO. A usual starting point is high-dose oral prednisone (1-2 mg/kg/day), although severe cases may be started on intravenous pulsed corticosteroids (methylprednisolone 1 g/day for three days) followed by oral prednisone. Topical corticosteroids and cycloplegics are used as adjuncts.

Most patients require long-term
treatment with a noncorticosteroid immunosuppressive agent such as azathioprine, methotrexate, or myco-
phenolate mofetil. Systemic corticoste-
roids are typically tapered over two to three months, whereas noncorticoste-
roid immunosuppressive agents tend to be continued for two or more years. More severe cases may require treat-
ment with a DNA crosslinking agent such as chlorambucil or a tumor nec-
rosis factor-alpha (TNF-α) inhibitor such as adalimumab or infliximab.5

Summary. The differential diag-
nosis for any postoperative or post-
traumatic bilateral panuveitis should include SO.6 Most cases occur within
three months of the inciting event, al-
though uveitis may appear many years later, as in this case. Medical therapy with systemic corticosteroids and noncorticosteroid immunosuppressive agents is the mainstay of treatment. ■

*Patient name is fictitious.


Dr. Rebong is a resident at California Pacific Medical Center (CPMC). Dr. Lowinger is assistant professor of ophthalmology at New England Eye Center and Tufts University School of Medicine. Dr. Haug is in private practice at West Coast Retina Medical Group. Dr. Cunningham is director of the uveitis service at CMPC, adjunct clinical professor of ophthalmology at Stanford University School of Medicine, and research associate at the Francis I. Proctor Foundation, UCSF School of Medicine, and sees patients in private practice at West Coast Retina Medical Group. They report no related financial interests.

Supported in part by the Pacific Vision Foundation and San Francisco Retina Foundation.